{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:06:34Z","timestamp":1790283994899,"version":"4.1.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006438","name":"Office of the Assistant Secretary for Health","doi-asserted-by":"publisher","award":["W81XWH2010284"],"award-info":[{"award-number":["W81XWH2010284"]}],"id":[{"id":"10.13039\/100006438","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["P30AR053503"],"award-info":[{"award-number":["P30AR053503"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R37NS041435"],"award-info":[{"award-number":["R37NS041435"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000890","name":"National Multiple Sclerosis Society","doi-asserted-by":"publisher","award":["Career Transition Award"],"award-info":[{"award-number":["Career Transition Award"]}],"id":[{"id":"10.13039\/100000890","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Peptidylarginine deiminase 2 (PAD2) mediates the post-translational conversion of arginine residues in proteins to citrullines and is highly expressed in the central nervous system (CNS). Dysregulated PAD2 activity has been implicated in the pathogenesis of several neurologic diseases, including multiple sclerosis (MS). In this study, we sought to define the cellular and regional expression of the gene encoding for PAD2 (i.e. <jats:italic>PADI2<\/jats:italic>) in the human CNS using publicly available datasets and evaluate whether anti-PAD2 antibodies were present in patients with various neurologic diseases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 491 study participants were included in this study: 91 people with MS, 32 people with neuromyelitis optica (NMO), 281 people with post-treatment Lyme disease (PTLD), and 87 healthy controls. To measure <jats:italic>PADI2<\/jats:italic> expression in the CNS from healthy individuals, publicly available tissue and single cell RNA sequencing data was analyzed. Anti-PAD2 antibodies were measured in the serum of study participants using anti-PAD2 ELISA. Clinical and demographic variables were compared according to anti-PAD2 antibody positivity for the MS and PTLD groups and correlations between anti-PAD2 levels and disease severity were examined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p><jats:italic>PADI2<\/jats:italic> expression was highest in oligodendrocytes (mean \u00b1 SD; 6.4 \u00b1 2.2), followed closely by astrocytes (5.5 \u00b1 2.6), microglia\/macrophages (4.5 \u00b1 3.5), and oligodendrocyte precursor cells (3.2 \u00b1 3.3). There was an increased proportion of anti-PAD2 positivity in the MS (19.8%; <jats:italic>p<\/jats:italic> = 0.007) and PTLD groups (13.9%; <jats:italic>p<\/jats:italic> = 0.057) relative to the healthy controls (5.7%), and these antibodies were not detected in NMO patients. There was a modest inverse correlation between anti-PAD2 levels and disease severity in people with MS (\u03c4 = \u22120.145, <jats:italic>p<\/jats:italic> = 0.02), with levels being the highest in those with relapsing-remitting disease. Similarly, there was a modest inverse correlation between anti-PAD2 levels and neurocognitive score (\u03c4 = \u22120.10, <jats:italic>p<\/jats:italic> = 0.027) in people with PTLD, with difficulty focusing, memory changes, fatigue, and difficulty finding words contributing most strongly to the effect.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p><jats:italic>PADI2<\/jats:italic> expression was observed in diverse regions and cells of the CNS, and anti-PAD2 autoantibodies were associated with less severe symptoms in subsets of patients with MS and PTLD. These data suggest that anti-PAD2 antibodies may attenuate inflammation in diseases of different etiologies, which are united by high <jats:italic>PADI2<\/jats:italic> expression in the target tissue.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2022.874211","type":"journal-article","created":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T07:11:00Z","timestamp":1654499460000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Peptidylarginine Deiminase 2 Autoantibodies Are Linked to Less Severe Disease in Multiple Sclerosis and Post-treatment Lyme Disease"],"prefix":"10.3389","volume":"13","author":[{"given":"Yaewon","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison W.","family":"Rebman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tory P.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Colantuoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavan","family":"Bhargava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Calabresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John N.","family":"Aucott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Soloski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Darrah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"700","DOI":"10.2174\/1389450116666150202160954","article-title":"Protein arginine deiminases and associated citrullination: physiological functions and diseases associated with dysregulation","volume":"16","author":"Witalison","year":"2015","journal-title":"Curr Drug Targets."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1016\/j.biocel.2006.03.008","article-title":"Citrullination: a posttranslational modification in health and disease","volume":"38","author":"Gyorgy","year":"2006","journal-title":"Int J Biochem Cell Biol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.2174\/0929867323666151118120710","article-title":"Peptidyl arginine deiminases and neurodegenerative diseases","volume":"23","author":"Tu","year":"2016","journal-title":"Curr Med Chem."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1074\/mcp.RA118.000696","article-title":"Mining the human tissue proteome for protein citrullination","volume":"17","author":"Lee","year":"2018","journal-title":"Mol Cell Proteomics."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1002\/bies.10357","article-title":"Pad, a Growing family of citrullinating enzymes: genes, features and involvement in disease","volume":"25","author":"Vossenaar","year":"2003","journal-title":"Bioessays."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.celrep.2019.03.108","article-title":"Pad2-mediated citrullination contributes to efficient oligodendrocyte differentiation and myelination","volume":"27","author":"Falcao","year":"2019","journal-title":"Cell Rep"},{"key":"B7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41586-019-1404-z","article-title":"Neuronal vulnerability and multilineage diversity in multiple sclerosis","volume":"573","author":"Schirmer","year":"2019","journal-title":"Nature."},{"key":"B8","doi-asserted-by":"publisher","first-page":"4422","DOI":"10.1073\/pnas.0509158103","article-title":"Deimination of membrane-bound myelin basic protein in multiple sclerosis exposes an immunodominant epitope","volume":"103","author":"Musse","year":"2006","journal-title":"Proc Natl Acad Sci USA."},{"key":"B9","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1750-3639.2007.00064.x","article-title":"The immunopathology of multiple sclerosis: an overview","volume":"17","author":"Lassmann","year":"2007","journal-title":"Brain Pathol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1177\/1352458511421055","article-title":"Methylation-dependent Pad2 upregulation in multiple sclerosis peripheral blood","volume":"18","author":"Calabrese","year":"2012","journal-title":"Mult Scler."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1002\/jnr.21329","article-title":"Peptidyl argininedeiminase 2 Cpg Island in multiple sclerosis white matter is hypomethylated","volume":"85","author":"Mastronardi","year":"2007","journal-title":"J Neurosci Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1007\/s11064-016-1920-2","article-title":"Myelin basic protein citrullination in multiple sclerosis: a potential therapeutic target for the pathology","volume":"41","author":"Yang","year":"2016","journal-title":"Neurochem Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"26430","DOI":"10.1038\/srep26430","article-title":"Abrogation of collagen-induced arthritis by a peptidyl arginine deiminase inhibitor is associated with modulation of t cell-mediated immune responses","volume":"6","author":"Kawalkowska","year":"2016","journal-title":"Sci Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"8876","DOI":"10.1021\/acs.jmedchem.7b01102","article-title":"Noncovalent protein arginine deiminase (Pad) inhibitors are efficacious in animal models of multiple sclerosis","volume":"60","author":"Tejeda","year":"2017","journal-title":"J Med Chem."},{"key":"B15","doi-asserted-by":"publisher","first-page":"4396","DOI":"10.4049\/jimmunol.1001620","article-title":"N-Alpha-benzoyl-N5-(2-Chloro-1-Iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis","volume":"186","author":"Willis","year":"2011","journal-title":"J Immunol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1093\/rheumatology\/kev440","article-title":"Increased Levels of Peptidylarginine deiminase 2 in synovial fluid from anti-Ccp-positive rheumatoid arthritis patients: association with disease activity and inflammatory markers","volume":"55","author":"Damgaard","year":"2016","journal-title":"Rheumatology."},{"key":"B17","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1136\/ard.2003.012211","article-title":"Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages","volume":"63","author":"Vossenaar","year":"2004","journal-title":"Ann Rheum Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/art.30081","article-title":"Immune complexes containing citrullinated fibrinogen costimulate macrophages via toll-like receptor 4 and fcgamma receptor","volume":"63","author":"Sokolove","year":"2011","journal-title":"Arthritis Rheum."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.3389\/fimmu.2018.02696","article-title":"Autoantibodies to peptidylarginine deiminase 2 are associated with less severe disease in rheumatoid arthritis","volume":"9","author":"Darrah","year":"2018","journal-title":"Front Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/B978-0-444-52001-2.00025-X","article-title":"Neuromyelitis optica (Devic's syndrome)","volume":"122","author":"Wingerchuk","year":"2014","journal-title":"Handb Clin Neurol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s11136-012-0126-6","article-title":"Post-treatment Lyme disease syndrome symptomatology and the impact on life functioning: is there something here?","volume":"22","author":"Aucott","year":"2013","journal-title":"Qual Life Res."},{"key":"B22","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/s12974-018-1381-4","article-title":"Imaging glial activation in patients with post-treatment lyme disease symptoms: a pilot study using [(11)C]Dpa-713 pet","volume":"15","author":"Coughlin","year":"2018","journal-title":"J Neuroinflammation."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.bbi.2010.03.002","article-title":"Anti-neural antibody reactivity in patients with a history of lyme borreliosis and persistent symptoms","volume":"24","author":"Chandra","year":"2010","journal-title":"Brain Behav Immun."},{"key":"B24","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1177\/1352458515600248","article-title":"Multiple sclerosis patients have a diminished serologic response to vitamin D supplementation compared to healthy controls","volume":"22","author":"Bhargava","year":"2016","journal-title":"Mult Scler."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology."},{"key":"B26","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3389\/fmed.2017.00224","article-title":"The clinical, symptom, and quality-of-life characterization of a well-defined group of patients with posttreatment Lyme disease syndrome","volume":"4","author":"Rebman","year":"2017","journal-title":"Front Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e95302","DOI":"10.1172\/jci.insight.95302","article-title":"Metabolic alterations in multiple sclerosis and the impact of vitamin D supplementation","volume":"2","author":"Bhargava","year":"2017","journal-title":"JCI Insight"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1212\/01.WNL.0000156155.19270.F8","article-title":"Multiple sclerosis severity score: using disability and disease duration to rate disease severity","volume":"64","author":"Roxburgh","year":"2005","journal-title":"Neurology."},{"key":"B29","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1001\/jama.1995.03530120023018","article-title":"Recommendations for test performance and interpretation from the second national conference on serologic diagnosis of Lyme disease","volume":"274","year":"1995","journal-title":"JAMA"},{"key":"B30","doi-asserted-by":"publisher","first-page":"D991","DOI":"10.1093\/nar\/gks1193","article-title":"Ncbi geo: archive for functional genomics data sets\u2013update","volume":"41","author":"Barrett","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"7285","DOI":"10.1073\/pnas.1507125112","article-title":"A survey of human brain transcriptome diversity at the single cell level","volume":"112","author":"Darmanis","year":"2015","journal-title":"Proc Natl Acad Sci USA."},{"key":"B32","volume-title":"R: A Language and Environment for Statistical Computing","author":"Team","year":"2019"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1038\/s41593-018-0197-y","article-title":"Developmental and genetic regulation of the human cortex transcriptome illuminate schizophrenia pathogenesis","volume":"21","author":"Jaffe","year":"2018","journal-title":"Nat Neurosci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nature11405","article-title":"An anatomically comprehensive atlas of the adult human brain transcriptome","volume":"489","author":"Hawrylycz","year":"2012","journal-title":"Nature."},{"key":"B35","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1001\/archneur.62.6.865","article-title":"Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement","volume":"62","author":"Freedman","year":"2005","journal-title":"Arch Neurol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s004150200026","article-title":"de los Milagros Bassani Molinas M","volume":"249","author":"Correale","year":"2002","journal-title":"J Neurol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/08916930410001713098","article-title":"Molecular mimicry to Borrelia Burgdorferi: pathway to autoimmunity?","volume":"37","author":"Bolz","year":"2004","journal-title":"Autoimmunity."},{"key":"B38","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1242\/dmm.000729","article-title":"Peptidylarginine deiminase 2 (Pad2) overexpression in transgenic mice leads to myelin loss in the central nervous system","volume":"1","author":"Musse AA Li","year":"2008","journal-title":"Dis Model Mech."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.874211\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T07:11:05Z","timestamp":1654499465000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.874211\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,6]]},"references-count":38,"alternative-id":["10.3389\/fneur.2022.874211"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.874211","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,6]]},"article-number":"874211"}}